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ABSTRACT 
 
Background: Chemotherapeutic drug like adriamycin, duanorubicin, 
idarubicin, epirubicin, and mitoxantrone are associated with acute, reversible 
cardiotoxic effects and a dose-related cardiac dysfunction/Cardiomyopathy. 
This entity is largely irreversible and cumulative and prevention is the most 
preferred strategy. Development of the same   can be largely averted by 
monitoring the left ventricular function by easily reproducible methods 
available with us as like 2D-Echocardiography. The incidence of 
Anthracycline induced cardiomyopathy (AIC) is in the range of 3-5% for 
clinical and 24-27% in Indian population.(Khattry et al., 2009) As not 
everyone who receives anthracyclines develop cardiotoxicity, the 
identification of a predictive test is required. A number of biomarkers like 
Troponin I, Creatine kinase -MB have been investigated to assess their utility 
as a potential biomarker for predicting the risk of developing Anthracycline 
induced Cardiomyopathy (AIC), but none have proved effective. The 
identification of a test that would predict patients likely to develop AIC would 
be particularly valuable in India given the high prevalence of subclinical 
cardiac dysfunction due to other causes such as diabetes mellitus.In this 
context a genetic study of Cardiomyopathy in  Indian population  found a 
specific 25- base pair deletion in the gene MYBPC3, which encodes Cardiac 
myosin binding protein C, a keyconstituent of cardiac sarcomere, This was 
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prevalent more commonly in the South Indian population.(Dhandapany et al., 
2009). DNA extraction was performed from peripheral blood sample of 18 
patients with documented AIC which was followed by PCR, Gel 
electrophoresis and Restriction digestion to look for the same specific 25-bp 
deletion in MYBPC3 gene  
RESULTS. 
 Analysis of outcomes of diffuse large B cell lymphoma and high 
grade follicular lymphoma treated with CHOP-based chemotherapy between 
2010- 2013: 
 The evaluable patients (n=227) with DLBCL and Grade 3 FL with 
chemotherapy regimen CHOP with or without Rituximab were included in the 
analysis. All patients were followed up until December 2014.A median follow 
up was 2.6 years..Majority of the patients 77%were below 60 years at 
presentation. 65% patients were males and  35% were females. B symptoms 
were present in (32%) of the patients at presentation.70 percent of patients 
presented in PS-1. Cervical lymphadenopathy was the most common 
presentation. Extranodal involvement was seen 23% of the patients and 
Gastrointestinal systemI was the  most common extranodal site. 55 % of 
patients presented with stageIII and IV disease and 37% patients had High 
risk IPI score.52 % patients received RCHOP and 48 percent  received 
CHOP. After treatment, 64% of patients CR and 20 percent were in partial 
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remission after all treatment.,Fifty five patients had Primary progressive 
disease. 
 In Univariate analysis, Patients with ECOG PS 0,1 had a better 3 
year  EFS and OS as compared to patients presenting with Poor ECOG 
PS(p<0.004). Patient presenting with Stage 1, 2 had a better outcome than  
patients presenting with stage 3 and 4)(p<0.001) .Patient with Low risk IPI 
score had better 3 year EFS and OS as compared to  a higher IPI . Number of 
extranodal sites and  Serum LDH did not have any significant impact on the 
outcome(p value 0.998 &0.114 respectively). 
 In multivariate analysis: model 1, where PS, Stage, LDH and 
chemotherapy were evaluated. Only chemotherapy (HR:1.991;CI:1.227-
3.233,p value<0.005) and PS(HR:2.04 ;CI 1.256-3.315,p value< 0.004 were 
significant. In model 2, where LDH was excluded, stage, 
PS(HR:2.4,CI:1.256- 3.315, p<0.004)and type of chemotherapy were 
significant (HR 1.991,CI:1.227-3.233 p< 0.005) 
 A separate analysis of 18 cases with Anthracycline induced 
Cardiomyopathy showed that Of the 18, MYBPC3 was detected using PCR in 
8 samples. The remaining samples were not analysable poor quality of DNA. 
A 928 base pair band was observed in all 8 samples which suggested the 
absence of 25 base pair deletion in any of these samples. This was further 
confirmed by a restriction digestion analysis using Bgl1 enzyme, which gave 
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a distinct restriction banding pattern as expected if MYBPC3 was wild type. 
In this group of 8 patients who had a satisfactory PCR there was no 
polymorphism (del 25bp) in the MYBPC3 gene. 
Conclusion of the study:  
 By Univariate analysis, Performance Status, IPI score, and type of 
chemotherapy  predicted survival. Most of these indirectly reflect the stage at 
presentation. Stage is probably the single most important predictor of survival 
in DLBCL. Older age at presentation(>60 years),Presence of more than one 
extranodal site and a Higher LDH at presentation were not found significant 
in Multivariate analysis. Twenty Five base pair deletion in the gene-MYBPC3 
which is indigenous to the cases with Cardiomyopathy in South Indians does 
not seem to responsible for development or worsening of Anthracycline 
induced cardiotoxicity. 
Keywords : DLBCL:Diffuse large B cell lymphoma, MYBPC3:Myosin 
binding protein C3, AIC: Anthracycline induced Cardiomyopathy, 
DCM:Dilated cardiomyopathy. 
 
 
  
